Saturday, January 11, 2014

M&A Boom Seen in 2014 as Drug Hunt Spurs Biotech Deals

From here:

That’s against a backdrop of patent expirations at some of the industry’s biggest companies. More than $60 billion in revenue was lost by the pharmaceutical industry to cheaper generic competition from 2010 to 2012, according to research by analysts at Bloomberg Industries. Another $50 billion may be lost in the next five years.

No comments:

Post a Comment